Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate

doi:10.5306/wjco.v8.i2.100

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8623)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

835

WORD

334

HTML

4629

Figures (1-3)

388

Tables (1-1)

235

Sum=6421

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1006

Download

1196

Sum=2202

Apr 10, 2017 (publication date) through Dec 28, 2024

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Clin Oncol. Apr 10, 2017; 8(2): 100-105
Published online Apr 10, 2017. doi: 10.5306/wjco.v8.i2.100

Full Size Figure Download Figure

Figure 3 Adapting the study data to our clinic. A proposed algorithm to treat second line metastatic renal cell carcinoma patients according to tumor growth rate and patients’ characteristics. TGR: Tumor-growth rate; TKI: Tyrosine kinase inhibitor; LEN: Lenvatinib; EVE: Everolimus.

Citation: Grande E, Martínez-Sáez O, Gajate-Borau P, Alonso-Gordoa T. Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate. World J Clin Oncol 2017; 8(2): 100-105
URL: https://www.wjgnet.com/2218-4333/full/v8/i2/100.htm
DOI: https://dx.doi.org/10.5306/wjco.v8.i2.100